This new study challenges long-standing beliefs about autism
Prior research has shown that people with autism spectrum disorder (ASD) often experience difficulties recognizing faces and even emotional responses. This, many speculate, is what leads individuals with autism to exhibit social communication problems.
But the problem with this understanding is that we've never had any clear evidence of how a brain affected by autism perceives the human face and body. This has left us with plenty of questions, but a new study led by Waseda University in Japan could prove this theory wrong and completely change everything we thought we know about how individuals with ASD perceive the faces and bodies of those around them.
Today's Top Deals
XGIMI Prime Day deals feature the new MoGo 4 and up to 42% off smart projectors
Best deals: Tech, laptops, TVs, and more sales
Best Ring Video Doorbell deals
Challenging long-held beliefs
The belief that individuals with ASD often suffer from social communication issues that are driven by how their brains perceive others is a long-standing one. However, as noted above, there's never been any scientific proof to back it up. In this new study from Waseda University, scientists took detailed neuroimages of 23 adults with ASD and compared them to the neuroimages of 23 typically developing (TD) adults. The results were not as different as expected.
The researchers note that when looking at the images, they expected to see differences in the lateral occipitotemporal cortex (LOTC). This region of the brain is known to represent the visual information the brain processes to perceive the human body. Until now, it was assumed that individuals with autism, or ASD, would have that information clustered in a different way within their LOTC.
However, that isn't the case at all. When looking at the data, the researchers found that individuals in the ASD and TD groups all showed similar structures of activations for their LOTCs. This could disprove the theory that individuals with ASD perceive the human body differently, thus leading to other social communication issues. The researchers also note that there were no significant differences in the size or strength of the activation of the LOTC in either group.
'These results suggest that adults with autism perceive visual body information in much the same way as neurotypical adults,' Professor Hirotaka Kurihara shared in a statement. '[This] challenges long-standing assumptions that differences in body-related perception contribute to social difficulties in ASD.'
To double-check the results, the researchers also looked at whether brain patterns could be linked to individual differences. However, they also found no strong connections in this area, either. So, while it is true that individuals with ASD might struggle to read emotions or intentions based on expressions and gestures, that struggle does not seem to be tied to how their brains perceive the human body or face, which could help further research dig deeper into what the actual underlying cause is.
We're still a long way from truly understanding autism and the overall affect it has on the individuals affected by it. But researchers are working hard to learn more. We've also seen some pretty amazing breakthroughs in AI development, including an AI that can detect autism just by looking at how you hold objects.
More Top Deals
Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98
See the
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Turkey unveils domestically built hypersonic missile
STORY: :: Turkey unveiled its first domestically built hypersonic missile at an international arms fair :: July 22, 2025 :: Istanbul, Turkey :: The missiles typically launch a warhead that travels at five times the speed of sound at low altitudes Footage released by the Turkish missile manufacturer Roketsan showed the new weapon, known as the Tayfun Block-4, being showcased at the International Defence Industry Fair (IDEF). Hypersonic missiles typically launch a warhead that travels at more than five times the speed of sound or about 3,850 mph, often maneuvering at relatively low altitudes. The United States, China, Russia and other countries have also been developing hypersonic weapons in recent years.
Newsweek
4 hours ago
- Newsweek
Mom Told Autistic Daughter May Never Talk, Unprepared for What Happens Next
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A mom who was told her autistic non-verbal daughter may never talk, could not believe what she captured one rainy Saturday afternoon. Samantha Start (@samninawolf), 30, posted a reel on Instagram sharing a moment she never thought would come: her daughter Nina's first words. In the clip, her 6-year-old can be heard finally saying phrases like "all gone" and "oh dear", followed by counting along with her mom using a colorful number chart—a huge milestone for the family. Nina, 6, pictured wearing pink children's romper with green dinosaurs on. Nina, 6, pictured wearing pink children's romper with green dinosaurs on. @samninawolf "I'll forever remember the date she spoke words to me because that was a date we never thought would come," the mom of two told Newsweek. Samantha, who is also mom to son Wolf with husband Robert, 34, explained that her daughter was diagnosed with autism when she was just two years old. "It's try and understand what she wants, but we communicate in different ways and have learnt to understand Nina's needs," she told Newsweek. Autism Spectrum Disorder (ASD) affects individuals in a variety of ways, including how they communicate, behave and interact with others. While some children with autism develop language typically, others remain non-verbal or minimally verbal. It's estimated that around 25 to 30 percent of individuals with autism are non-verbal or have very limited verbal abilities, according to the Centers for Disease Control and Prevention (CDC). "We haven't vocally communicated in the whole six years she has been alive, so we don't know any different," Samantha added. After six years of silence, Nina's first words were a real breakthrough. "I was so shocked [at] how clear her speech was and just so happy to finally hear her speak," Samantha said. "I've waited six years for this day." Nina's first words had been watched over 376,000 times and received over 11,000 likes online at the time of writing. Hundreds commented on the clip, with many parents saying it's given them hope. "Oh my gosh, I dream of this day! How incredibly special," one user wrote. "Music to your ears! Her sweet little voice finding its way to you," another added. A third user commented, "This is so so amazing! Gives me so much hope for my autistic son." While Samantha was elated, the moment meant even more to Nina's younger brother. "It means so much to us as a family but especially her little brother who has longed for her to speak to him," she said. "He was so happy." Do you have funny and adorable videos or pictures you want to share? Send them to life@ with some extra details, and they could appear on our website.
Medscape
6 hours ago
- Medscape
What Factors Influence a Patient's Success on GLP-1s?
Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).
